Pre-Trials Research

Enzon Presents New PEG-SN38 Preclinical Data at ASH

Published in Law and Health Weekly, December 29th, 2007

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced new preclinical data showing that treatment with PEG-SN38, Enzon's PEGylated SN38 compound, resulted in excellent antitumor activity in xenograft models of non-Hodgkin's lymphoma (NHL). The data were presented at the ASH (American Society of Hematology) Conference in Atlanta, Georgia.

"The data further demonstrate the novel characteristics of our pegylated form of SN38, as this type of response by this class of drugs in NHL models is not expected," said Jeffrey H. Buchalter, Enzon's chairman and chief executive officer. "We continue to be encouraged by the positive preclinical results and await the completion of our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2007-12-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry